Results 51 to 60 of about 161,416 (241)

TGFBI Maintains Fibrocartilage Homeostasis by Restraining O‐GlcNAcylation to Inactivate and Destabilize ADAMTS16 in Temporomandibular Joint Osteoarthritis

open access: yesAdvanced Science, EarlyView.
TGFBI deficiency elevates O‐GlcNAcylation, promoting the transcriptional activation of ADAMTS16 and OGT‐mediated post‐translational modification of ADAMTS16 at Ser1170. This leads to its stabilization and accumulation, driving chondrocyte metabolic disorders and senescent phenotypes, ultimately resulting in fibrocartilage dysfunction and TMJOA ...
Xin Liu   +12 more
wiley   +1 more source

Fuchs Dystrophy and Cataract: Diagnosis, Evaluation and Treatment

open access: yesOphthalmology and Therapy, 2023
Corneal endothelium plays an important role in maintaining hydration homeostasis and clarity of the cornea. Fuchs endothelial corneal dystrophy (FECD) affects the corneal endothelium resulting in edema and characteristic excrescences on the Descemet’s ...
Muhammad Ali   +2 more
doaj   +1 more source

Scratched cornea: Case report on incidental bilateral posterior polymorphous corneal dystrophy

open access: yesIndian Journal of Ophthalmology. Case Reports, 2023
Posterior polymorphous corneal dystrophy (PPCD) is a dominantly inherited corneal endothelial disorder, typically considered bilateral and asymptomatic.
Aakash Chowdhary   +3 more
doaj   +1 more source

Self‐Propelled HPB@Lip@AB Nanomotors Ameliorate Dry Eye Disease

open access: yesAdvanced Science, EarlyView.
A self‐propelled HPB@Lip@AB nanomotor system is developed for dry eye disease (DED) therapy, facilitating rapid penetration across ocular surface barriers while integrating hydrogen therapy with multi‐enzyme‐like antioxidant activity. The nanoplatform restores mitochondrial function, suppresses oxidative stress, inflammation, and apoptosis, and ...
Jing Li   +9 more
wiley   +1 more source

Evaluation of corneal transplantation [PDF]

open access: yes, 1997
Editorial / comment on corneal ...
Coster, Douglas John
core  

Macrophage Dab1 Links Early Hypoxia to Adaptive Angiogenesis to Drive Peripheral Nerve Repair

open access: yesAdvanced Science, EarlyView.
Schematic diagram illustrating the Dab1‐linked hypoxia signaling pathway that accelerates angiogenesis and consequent nerve regeneration. Following PNI, a hypoxic microenvironment develops. Hypoxia induces macrophage Dab1 phosphorylation, resulting in NHE‐1 upregulation, HIF‐1α stabilization, and VEGF‐A expression. This cascade promotes angiogenesis in
Xiongyao Zhou   +14 more
wiley   +1 more source

Riboflavin concentration in corneal stroma after intracameral injection [PDF]

open access: yesInternational Journal of Ophthalmology, 2015
AIM:To evaluate the enrichment of riboflavin in the corneal stroma after intracameral injection to research the barrier ability of the corneal endothelium to riboflavin in vivo.METHODS:The right eyes of 30 New Zealand white rabbits were divided into ...
Na Li   +5 more
doaj   +1 more source

Developing novel culture substrates for in vitro construction of corneal endothelium [PDF]

open access: yes
The corneal endothelium plays a pivotal role in maintaining ocular clarity. However, its limited regenerative capacity in humans necessitates innovative therapeutic strategies.
Dai, Siqi
core   +1 more source

Neurovascular coupling in bone regeneration: Mechanisms, advanced biomaterials and challenges

open access: yesBMEMat, EarlyView.
This figure illustrates various material strategies for neurovascularized bone regeneration, including electroactive scaffolds, ion‐loaded materials, drug delivery systems, surface modifications, cells/cell products, growth factors, and peptides. These approaches aim to synergistically promote the regeneration of neural, vascular, and bone tissues ...
Yixin Ma   +8 more
wiley   +1 more source

The Multiple Criteria Qualitative Value‐Based Pricing Framework “MARIE” for Novel Cell and Gene Therapy

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
When setting the price of cell and gene therapies in Japan, the factors considered include the manufacturing and operating costs of the new drug or a comparator, leading to discrepancies between price and values, in particular those specific to cell and gene therapies.
Akina Takami, Ataru Igarashi
wiley   +1 more source

Home - About - Disclaimer - Privacy